White Paper

Targeting Leishmaniasis with an Entamoeba Molecule


Current treatment approaches for leishmaniasis, a parasitic disease, consist mainly of chemotherapeutics, which can cause severe side effects for patients and many perennial challenges for clinicians. This underscores the need for researchers to investigate new therapeutic methods that could be used independently or in conjunction with chemotherapeutics.

Learn about the promising results Dr. Helena Fehling from the Department of Molecular Parasitology and Immunology at the Bernhard Nocht Institute for Tropical Medicine, is finding with an immune-therapeutic approach to leishmaniasis treatment.